Lumos Diagnostics Holdings Ltd. · ASX:LDX
Lumos Diagnostics — Shareholder Meeting (November 2023)
18 slides from Lumos Diagnostics's shareholder meeting presentation, Nov 2, 2023
Slide 1: Annual General Meeting – CEO Presentation
For personal use only Lumos Diagnostics Holdings Limited Annual General Meeting – CEO Presentation November 2023 www.lumosdiagnostics.com Confidential. This document and supporting materials contain confidential and proprietary business information from Lumos. 1
Slide 2: Disclaimer and Important Information
Disclaimer and Important Information This presentation (Presentation) has been prepared solely for informational purposes by Lumos Diagnostics Holdings Limited (Company). The information contained in this document (“Document”) has been prepared by Lumos Diagnostics Holdings Limited (referred to as “
Slide 3: Board of Directors
Board of Directors For personal use only Sam Lanyon Doug Ward Bronwyn Le Grice Lawrence Mehren Catherine Robson Non-Executive CEO and Non-Executive Non-Executive Non-Executive Chair Managing Director Director Director Director 3
Slide 4: FY23 - Summary of Achievements
FY23 - Summary of Achievements “ The opportunity that Lumos has For personal use only with its technology, know-how US$10.2 million Commercial Services revenue in FY23 9% increase vs FY22 and expertise in the development and production of point-of-care diagnostic tests and its unique Completed reorg
Slide 5: Lumos has a compelling and highly competitive offering
Lumos has a compelling and highly competitive offering 1. Fully-integrated—from design to manufacturing 2. Proprietary reader platform for use in different settings For personal use only Strategic Product Commercial Innovation Development Manufacturing Single-use Multi-use disposable Desktop readers
Slide 6: Lumos' POC diagnostic test development engine
Lumos’ POC diagnostic test development engine For personal use only Design Develop Manufacture Product concepts REVENUE Contract Fees Margin Sales & license payments STREAMS from services from manufacturing from own & other products 6
Slide 7: Favourable industry structure and key trends
Favourable industry structure and key trends Robust underlying category growth forecast For personal use only GLOBAL POC DIAGNOSTIC TEST SALES • Significant growth anticipated from growing role of diagnostic tests in healthcare • Rapid, point-of-care tests increasingly being used – common in US sett
Slide 8: FY23 – Financial Result Highlights
FY23 – Financial Result Highlights* “ For personal use only While Lumos went into Revenue US$10.5 million (US$11.6 million FY22, incl. CoviDx US$1.7m), revenue from services up 9% FY2023 facing a number of challenges, I am extremely Gross profit margin for FY23 of 56%, an improvement of 12% over FY2
Slide 9: Commercial Services - FY23 Operational Summary
Commercial Services - FY23 Operational Summary • Lumos commercial services revenue of US$10.2 million – For personal use only an increase of 9% from FY22 • Completed major reorganisation which included reduction of headcount by over 60% • Closed Sarasota FL facility and consolidated operations to si
Slide 10: Strategic partnerships are a key pillar of Lumos' growth plan
Strategic partnerships are a key pillar of Lumos’ growth plan Lumos provides a compelling service offering for leading diagnostics companies For personal use only • Fully-integrated offering—from concept-to-clinic-to-commercial production • Proprietary reader platform—integrate POC testing with elec
Slide 11: Lumos has established a strategic partnership with Hologic
Lumos has established a strategic partnership with Hologic • Hologic is a recognized global leader in women’s health based in Massachusetts For personal use only - NASDAQ: HOLX, Market Capitalization US$20 billion - FY2022 revenue of US$4.2 billion with net income of US$1.3 billion - Diagnostic prod
Slide 12: FebriDx – Lumos' POC test to aid antibiotic prescribing
FebriDx – Lumos’ POC test to aid antibiotic prescribing • FebriDx offers an aid for healthcare providers to improve patient care and antibiotic stewardship For personal use only - 211 million outpatient antibiotic prescriptions in the US in 20211 - 40% antibiotics prescribed in for respiratory infec
Slide 13: Current Antibiotic prescribing in the US
Current Antibiotic prescribing in the US ANTIBIOTICS PRESCRIBED IN THE U.S. BY TYPE ANTIBIOTICS PRESCRIBED For personal use only Common cold antibiotic prescriptions issued in Sinusitis 211M outpatient settings each year 1 Other infections Bronchitis Sore throat Ear infection 44% of antibiotic presc
Slide 14: FebriDx – preparations for US launch well advanced
FebriDx – preparations for US launch well advanced • Scaling up production to meet additional anticipated demand For personal use only - Materials ordered for increased volume of production - Test strip optimisation currently underway - On track to have units available for initial orders expected in
Slide 15: ViraDx – Lumos' POC test for key respiratory infections
ViraDx™ – Lumos’ POC test for key respiratory infections • ViraDx highly relevant POC test for post-pandemic environment: For personal use only - SARS-CoV-2 pandemic increased consumer and healthcare POC testing - ViraDx is a 3-in-1 test for COVID-19/’flu A/’flu B - One of two tests available in mar
Slide 16: Lumos' direct US sales channel
Lumos’ direct US sales channel • Low-cost, targeted sales channel For personal use only - Targeting urgent care and relevant physician offices - Two internal FTEs (Head of Sales, Regional Manager) - Currently 7 commission-only reps — will increase over time - Two distributors signed, ten at final ne
Slide 17: Promising Outlook
Promising Outlook “ For personal use only We have come out of FY2023 a Expand and diversify pipeline of commercial services projects and recurring revenue much stronger and more focused company with an exciting pipeline of opportunities in front of us. Continue to build foundation for long-term grow
Slide 18: For personal use only
For personal use only www.lumosdiagnostics.com 18
Lumos Diagnostics Holdings — Shareholder Meeting (November 2023) on 6ix